Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday.

EGRX has been the subject of several other reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $86.00 price objective on shares of Eagle Pharmaceuticals in a report on Thursday, March 2nd. Mizuho upped their price objective on shares of Eagle Pharmaceuticals from $64.00 to $66.00 and gave the stock an “underperform” rating in a report on Monday, February 27th. Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Piper Jaffray Companies set a $118.00 price objective on shares of Eagle Pharmaceuticals and gave the stock an “overweight” rating in a report on Tuesday, May 9th. Finally, ValuEngine raised shares of Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $90.00.

Shares of Eagle Pharmaceuticals (EGRX) traded up 4.88% on Wednesday, hitting $80.78. 388,440 shares of the stock were exchanged. The firm’s 50-day moving average is $78.99 and its 200-day moving average is $77.77. Eagle Pharmaceuticals has a one year low of $34.20 and a one year high of $97.15. The company has a market cap of $1.24 billion, a P/E ratio of 12.70 and a beta of 1.48.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.44 by $0.02. The company had revenue of $76.80 million during the quarter, compared to analyst estimates of $70.10 million. Eagle Pharmaceuticals had a net margin of 44.48% and a return on equity of 79.25%. The firm’s quarterly revenue was up 159.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) EPS. On average, equities analysts forecast that Eagle Pharmaceuticals will post $3.66 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/06/21/eagle-pharmaceuticals-inc-egrx-upgraded-to-buy-at-bidaskclub.html.

In other news, major shareholder Proquest Investments Iv, L.P. sold 1,200 shares of the firm’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $83.05, for a total transaction of $99,660.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Pete A. Meyers acquired 350 shares of Eagle Pharmaceuticals stock in a transaction dated Monday, June 12th. The shares were acquired at an average cost of $71.49 per share, with a total value of $25,021.50. Following the completion of the acquisition, the chief financial officer now directly owns 350 shares in the company, valued at approximately $25,021.50. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 805 shares of company stock valued at $61,790 and sold 312,918 shares valued at $26,245,889. 18.80% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in EGRX. Thrivent Financial for Lutherans increased its position in Eagle Pharmaceuticals by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $333,000 after buying an additional 60 shares during the last quarter. Louisiana State Employees Retirement System increased its position in Eagle Pharmaceuticals by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 3,300 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System increased its position in Eagle Pharmaceuticals by 2.4% in the first quarter. Arizona State Retirement System now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $348,000 after buying an additional 100 shares during the last quarter. Texas Permanent School Fund increased its position in Eagle Pharmaceuticals by 2.2% in the first quarter. Texas Permanent School Fund now owns 5,867 shares of the specialty pharmaceutical company’s stock worth $487,000 after buying an additional 125 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in Eagle Pharmaceuticals by 2.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 5,305 shares of the specialty pharmaceutical company’s stock worth $421,000 after buying an additional 150 shares during the last quarter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.